Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : U.S. FDA advisers to vote on J&J COVID-19 vaccine booster

10/15/2021 | 11:51am EST

Oct 15 (Reuters) - A panel of expert advisers to the U.S. Food and Drug Administration will vote later on Friday on whether to recommend authorization of a booster shot of Johnson & Johnson's single-dose COVID-19 vaccine for people aged 18 and older, as well as the appropriate interval between the two doses.

The FDA's advisers will vote on whether to recommend the booster shot be given at least two months or at least six months after the first dose.

The FDA is not bound to follow their recommendations, but typically does.

At Friday's meeting, the panel will also discuss the merits of mixing vaccines from different manufacturers, so that an individual would get a booster that was not the same as their initial inoculation. They will consider data from a National Institutes of Health study of 458 participants that received some combination of Pfizer/BioNTech, Moderna and J&J shots.

Data from the study suggested that people who got J&J's COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer or Moderna.

J&J scientist Dr. Johan Van Hoof said it was difficult to be conclusive about the benefits and risks of mixing the vaccines, and said evidence supported J&J vaccine recipients getting a second dose of the same vaccine.

On Thursday, the panel unanimously backed https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-advisers-weigh-case-covid-19-vaccine-booster-shots-2021-10-14 booster shots of Moderna's COVID-19 vaccine for Americans aged 65 and older and those at high risk of severe illness or occupational exposure to the virus.

If the FDA signs off on the boosters, the U.S. Centers for Disease Control and Prevention will make specific recommendations on who should get the shots. CDC advisers are scheduled to meet to discuss the boosters next week.

The U.S. health agencies authorized boosters of the Pfizer/BioNTech vaccine last month.

U.S. health officials have been under pressure to authorize the additional shots after the White House announced plans in August for a widespread booster campaign pending approvals from the FDA and the CDC. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Caroline Humer, Chizu Nomiyama and Bill Berkrot)

ę Reuters 2021
All news about MODERNA, INC.
12/03U.S. administers 466.3 mln doses of COVID-19 vaccines - CDC
12/03U.S. CDC Says Delivered 580,893,145 Doses Of Covid-19 Vaccine As Of Dec 3
12/03U.S. CDC Reports Total Novel Coronavirus Cases Of 48,767,329 As Of Yesterday
12/03Vaccine makers could make Omicron-specific booster, says Fauci
12/03PUMP / DUMP #13 : This week's gainers and losers
12/03UK jabs deal to 'future-proof' immunisation
12/02Pfizer-BioNTech, Moderna's COVID-19 Jabs Offer Best Immunity Boost, UK Study Says
12/02U.S. administers 464.4 mln doses of COVID-19 vaccines - CDC
12/02U.S. CDC Says Delivered 578,263,565 Doses Of COVID-19 Vaccine As Of Dec 2
12/02US Stocks Rebound Following Recent Sell-Offs as Omicron Variant Concerns Subside
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 169 M - -
Net cash 2021 12 344 M - -
P/E ratio 2021 11,7x
Yield 2021 -
Capitalization 124 B 124 B -
EV / Sales 2021 6,42x
EV / Sales 2022 4,93x
Nbr of Employees 1 300
Free-Float 90,5%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 18
Last Close Price 306,72 $
Average target price 272,53 $
Spread / Average Target -11,1%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298